Nurix Gross Profit from 2010 to 2025

NRIX Stock

USD 13.15 0.16 1.23%

Nurix Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Nurix Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2019-08-31

Previous Quarter

8.4 M

Current Value

13.3 M

Quarterly Volatility

5.4 M

Covid

Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.

Check out the analysis of Nurix Therapeutics Correlation against competitors.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Latest Nurix Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Nurix Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Nurix Therapeutics minus its cost of goods sold. It is profit before Nurix Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Nurix Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (167.08 M)

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

Nurix Gross Profit Regression Statistics

	Arithmetic Mean	25,931,869
	Geometric Mean	37,757,280
	Coefficient Of Variation	154.16
	Mean Deviation	23,255,826
	Median	37,449,000
	Standard Deviation	39,976,137
	Sample Variance	1598.1T
	Range	166.7M
	R-Value	(0.16)
	Mean Square Error	1666.2T
	R-Squared	0.03
	Significance	0.54
	Slope	(1,376,473)
	Total Sum of Squares	23971.4T

Nurix Gross Profit History

	2025	51.5 M
	2024	49.1 M
	2023	54.5 M
	2022	-112.2 M
	2021	38.6 M
	2020	29.8 M
	2019	17.8 M

Other Fundumenentals of Nurix Therapeutics

Gross Profit Margin

Nurix Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.86	0.7	-0.77	-0.91	0.97	0.98	0.95	0.88	1.0	0.99	0.99	0.99	0.76	0.99	0.8	-0.88	-0.67
Total Stockholder Equity	1.0		0.86	0.7	-0.78	-0.9	0.97	0.98	0.94	0.86	1.0	0.99	0.99	0.99	0.74	0.99	0.79	-0.86	-0.67
Net Tangible Assets	0.86	0.86		0.81	-0.74	-0.79	0.76	0.78	0.93	0.89	0.86	0.8	0.86	0.8	0.89	0.86	0.9	-0.82	-0.28
Current Deferred Revenue	0.7	0.7	0.81		-0.38	-0.72	0.67	0.67	0.79	0.74	0.7	0.67	0.72	0.64	0.74	0.72	0.79	-0.77	-0.3
Net Debt	-0.77	-0.78	-0.74	-0.38		0.52	-0.63	-0.67	-0.66	-0.55	-0.78	-0.73	-0.72	-0.75	-0.5	-0.72	-0.49	0.43	0.38
Retained Earnings	-0.91	-0.9	-0.79	-0.72	0.52		-0.94	-0.95	-0.93	-0.9	-0.9	-0.93	-0.94	-0.92	-0.81	-0.94	-0.77	0.97	0.57
Accounts Payable	0.97	0.97	0.76	0.67	-0.63	-0.94		0.99	0.91	0.88	0.97	0.99	0.98	0.98	0.7	0.98	0.76	-0.89	-0.74
Short Term Investments	0.98	0.98	0.78	0.67	-0.67	-0.95	0.99		0.92	0.86	0.98	1.0	0.99	0.99	0.71	0.99	0.73	-0.89	-0.73
Capital Surpluse	0.95	0.94	0.93	0.79	-0.66	-0.93	0.91	0.92		0.92	0.94	0.93	0.97	0.92	0.91	0.97	0.87	-0.95	-0.55
Total Liab	0.88	0.86	0.89	0.74	-0.55	-0.9	0.88	0.86	0.92		0.86	0.86	0.9	0.85	0.88	0.9	0.88	-0.89	-0.44
Net Invested Capital	1.0	1.0	0.86	0.7	-0.78	-0.9	0.97	0.98	0.94	0.86		0.99	0.99	0.99	0.74	0.99	0.79	-0.86	-0.67
Total Current Assets	0.99	0.99	0.8	0.67	-0.73	-0.93	0.99	1.0	0.93	0.86	0.99		0.99	1.0	0.71	0.99	0.73	-0.87	-0.72
Capital Stock	0.99	0.99	0.86	0.72	-0.72	-0.94	0.98	0.99	0.97	0.9	0.99	0.99		0.99	0.79	1.0	0.79	-0.91	-0.68
Net Working Capital	0.99	0.99	0.8	0.64	-0.75	-0.92	0.98	0.99	0.92	0.85	0.99	1.0	0.99		0.7	0.99	0.72	-0.86	-0.72
Short Term Debt	0.76	0.74	0.89	0.74	-0.5	-0.81	0.7	0.71	0.91	0.88	0.74	0.71	0.79	0.7		0.79	0.8	-0.88	-0.31
Common Stock	0.99	0.99	0.86	0.72	-0.72	-0.94	0.98	0.99	0.97	0.9	0.99	0.99	1.0	0.99	0.79		0.79	-0.91	-0.68
Property Plant Equipment	0.8	0.79	0.9	0.79	-0.49	-0.77	0.76	0.73	0.87	0.88	0.79	0.73	0.79	0.72	0.8	0.79		-0.84	-0.27
Net Receivables	-0.88	-0.86	-0.82	-0.77	0.43	0.97	-0.89	-0.89	-0.95	-0.89	-0.86	-0.87	-0.91	-0.86	-0.88	-0.91	-0.84		0.52
Deferred Long Term Liab	-0.67	-0.67	-0.28	-0.3	0.38	0.57	-0.74	-0.73	-0.55	-0.44	-0.67	-0.72	-0.68	-0.72	-0.31	-0.68	-0.27	0.52

Click cells to compare fundamentals

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	49.1 M	51.5 M
Gross Profit Margin	(1.31)	(1.25)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC